Lantern Pharma Reports $0.7M Net Income, Flags Going-Concern Doubt
Lantern Pharma reported Q3 net income of $0.7 million, versus a $4.2 million net loss a year earlier, including an approximately $6.0 million non-cash warrant gain. Cash, equivalents and marketable securities were $7.6 million, down from $10.1 million at year-end 2025; the company said funding is insufficient for the next 12 months.
Lantern Pharma reported Q3 net income of $0.7M, versus a $4.2M net loss a year earlier, including a non-cash warrant gain of approximately $6.0M. Cash, equivalents and marketable securities were $7.6M, down from $10.1M at year-end 2025; the company said funding is insufficient for the next 12 month…